Fármacos en el Tratamiento del EPOC: Una Revisión de la Terapia Farmacológica colombiana

Ana Patricia Cáceres Cortes; Gabriel Felipe Báez Ardila; Santiago Antonio Molina Ochoa; Sergio Andrés Hernández Zapata

doi:10.22490/26194759.9159

Vol. 8 No. 1 (2024)

Published 2024-12-27

license

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Artículos

Drugs in the Treatment of COPD: A Review of Colombian Drug Therapy

DOI: https://doi.org/10.22490/26194759.9159

Ana Patricia Cáceres Cortes Corporación Universitaria Iberoamericana

Gabriel Felipe Báez Ardila Corporación Universitaria Iberoamericana

Santiago Antonio Molina Ochoa Corporación Universitaria Iberoamericana

Sergio Andrés Hernández Zapata Corporación Universitaria Iberoamericana

PDF (Spanish)

Abstract
References

Chronic obstructive pulmonary disease (COPD) is a respiratory disorder known worldwide for a persistent limitation in airflow, associated with symptoms such as dyspnea, sputum production and chronic cough, which is generated by a chronic and progressive decrease in the bronchial lumen. COPD brings with it complications such as exacerbations, worsening of the patient's prognosis, deterioration of lung function, thus leading to a reduction in the quality of life of these patients.

The purpose of this review is to identify and analyze the pharmacological treatments available in the literature, their influence on symptoms, safety, patterns of use of the most commonly prescribed medications and the improvement of lung function during the years 2016-2024. Articles in English and Spanish are included in databases such as PubMed, Scopus, Dialnet, Google Sholar and Scielo.

The evidence reviewed indicates that inhaled medications, especially in combination, are essential in the management of COPD in Colombia. Triple therapy and LABA/LAMA combinations have been shown to be the most effective options for controlling symptoms and reducing exacerbations, whereas inhaled corticosteroids should be used with caution and only in patients where their benefit is clear. These findings suggest an advance in therapeutic strategies towards personalized management of COPD, aligned with international guidelines and adapted to local needs.

keywords: COPD, tratment, drug

Global Intiative for chronic obstructive lung disease. (2024). Guía de bolsillo para el diagnóstico, manejo y prevención del EPOC. Global Intiative for chronic obstructive lung disease. Edición 2024, 1-28.https://goldcopd.org/wp-content/uploads/2024/04/GOLD-2024_v2.1_04.24.24_WMV.pdf

Minsalud y Protección Social (2015). Nunca es demasiado tarde." Para que mejores tu salud respiratoria, en cualquier etapa, bien sea antes o después de un diagnóstico de EPOC. Ministerio de Salud, 1.https://www.minsalud.gov.co/Regiones/Paginas/MinSalud-promueve-control-de-enfermedad-pulmonar-obstructiva-crónica---EPOC.aspx#:~:text=Es%20la%20cuarta%20causa%20de,y%20son%20atribuidas%20a%20tabaco

Gil-Rojas, Y., Torres-Duque, C.A., Figueredo, M., Hernández, F., Castañeda-Carona, C., Lasalvia, P., Rosselli, D. (2019). Estimación de la prevalencia de EPOC en Colombia a partir del Registro Individual de Prestaciones de Servicios de Salud (RIPS). Revista Colombiana de Neumología, 30(1), 5 - 15. https://doi.org/10.30789/rcneumologia.v31.n1.2019.325

Díaz Santos, G., Pacheco, M., García, M., Rubio Rubio, R., Contreras, R. D., Ariza, W., Acero, R., Lázaro, T., Mier Osejo, J. E., Pedrozo, J., Forero, J., Manrique, L., Romero, M., Alvarado, J., Alvarado, J., Aguirre, C., Rada, R., Baños Álvarez, I. de J., Celis, C., Vanegas, A. C., Matiz, C., Hincapié Díaz, G. A., Casas, A., y Alí Munive, A. (2021). Enfermedad pulmonar obstructiva crónica durante la pandemia de coronavirus 2020. Revista Colombiana de Neumología, 32(1), 43–46. https://doi.org/10.30789/rcneumologia.v32.n1.2020.508

Molina-Franky J., Roa-Cubaque M. A., Corredor-Gamba S. P, Polanía-Robayo A. Y., Rojas-Laverde M del P. (2018). Tratamiento farmacológico y no farmacológico de la enfermedad pulmonar obstructiva crónica.Revista Investigación en Salud Universidad de Boyacá, 5(2), 295-322. https://doi.org/10.24267/23897325.345

García-Morales O.M., Ali-Munive A., Celis-Preciado C.A., Londoño-Trujillo D., Casas A., Bastidas-Goyes A., Aguirre-Franco C., Torres C.A., Baños-Álvarez I.D.J., Pedrozo-Pupo J.C., Manrique-Acevedo L., Pacheco-Gallego M.C., Acero R., Contreras-Páez R., Bohórquez J.V., Chaves W., Rivera F., Betancourt-Peña J., Yepes-Núñez J.J., ... Rubiano W. (2024). Guía de práctica clínica sobre el diagnóstico, manejo y seguimiento de la enfermedad pulmonar obstructiva crónica en Colombia 2023. Revista Colombiana de neumología, 35(2). 2023, 59 - 63. https://doi.org/10.30789/rcneumologia.v35.n2Supl-1.2023.984

Castrillón-Spitia J., Ramírez, A., Garzón-Rojas A., Arias-Hernández A., Trejos-Rojas C., Restrepo-Gaviria M., Trejos-Ramírez M., Conrado-Gallego M. (2023). Uso de inhaladores para la enfermedad pulmonar obstructiva crónica en un grupo de pacientes colombianos. Salud UIS, 55 (2023), 1 - 9. https://doi.org/10.18273/saluduis.55.e:23055

Montes-Cardona J. A, Hincapié-Erira D, A., Nati-Castillo H. A., Sánchez-Vallejo J., Izquierdo-Condoy J. S. (2023). Characteristics of Inhaler Technique in COPD Patients in a Specialized Center in Armenia, Colombia: A Cross-Sectional Study. Patient Prefer Adherence, 2023(17), 2025-2038. https://doi.org/10.2147/PPA.S417375

Dreyse J. (2024). Manejo de la EPOC en la era moderna. Revista Médica Clínica Las Condes, 35(3 - 4), 209 - 220. https://doi.org/10.1016/j.rmclc.2024.05.002

Orozco-Levi, M., Colmenares-Mejía, C., Ruíz, J., Valencia-Barón, Y. D., Ramírez-Sarmiento, A., Quintero-Lesmes, D., & Serrano, N. C. (2021). Effect of Antioxidants in the Treatment of COPD Patients: Scoping Review. Journal of Nutrition and Metabolism, 2021(7463391), 1 - 15. https://doi.org/10.1155/2021/7463391

Celis-Preciado, C. A. (2016). Descontinuación del esteroide inhalado en pacientes con enfermedad pulmonar obstructiva crónica moderada a severa no aumenta el riesgo de exacerbaciones. Revista Colombiana de Neumología, 26(4), 183 - 187. https://doi.org/10.30789/rcneumologia.v26.n4.2014.9

Jian-Jun Wu, Ping-An Zhang, Ming-Zhe Chen, Wei-Sha Du, Yi Zhang, Yang Jiao, Xin Li. (2025). Network Pharmacology and Experimental Validation of Jinwei Decoction for Enhancement of Glucocorticoid Anti-Inflammatory Effect in COPD through miR-155-5p. Combinatorial Chemistry & High Throughput Screening, 28(2), 351–370. https://doi.org/10.2174/0113862073279344240215050056

Machado-Duque M. E., Gaviria-Mendoza A., Valladales-Restrepo L. F., González-Rangel A., Laucho-Contreras M. E., Machado-Alba J. E. (2023). Patterns and Trends in the Use of Medications for COPD Control in a Cohort of 9476 Colombian Patients, 2017–2019. International Journal of Chronic Obstructive Pulmonary Disease. 2023(18), 1601-1610. https://doi.org/10.2147/COPD.S391573

Abdul-Aziz M. I, Tan L. E., Wu-D. B., Pearce F., Chua G. S. W., Lin L., Tan P. T., Ng K. (2018). Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2018(13) 3203-3231. https://doi.org/10.2147/COPD.S173472

Aguilar-Shea A. L., Gallardo-Mayo C. (2022). Revisión narrativa de la terapia inhalatoria en la EPOC. Medicina de Familia, SEMERGEN, 48 (3), 214 - 218. https://doi.org/10.1016/j.semerg.2021.08.001

Grupo de Trabajo de GesEPOC, Working group of the GesEPOC. (2017). Tratamiento de la EPOC Estable. Archivos de Bronconeumología. 53(1), 23-33. https://doi.org/10.1016/S0300-2896(17)30361-7

Kocks, J., Bosnic-Anticevich, S.,van Cooten, J, Correia de Sousa J., Cvetkovski B., Dekhuijzen R., Dijk L., Garcia-Pardo M., Gardev A., Gawlik R., Van der Ham I., Janse Y., Lavorini F., Maricoto T., Meijer J Metz B., Price D., Roman-Rodriguez M., Schuttel K, ... Leving M, L. (2023). Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. BMC Pulmonary Medicine 23(302), 1 - 15. https://doi.org/10.1186/s12890-023-02566-6

Maldonado-Mariño E. V., Medina-Aldaz A. M., Guato-Canchinia D. E., Suárez-Páez D. A. (2024). New pharmacological therapies for the treatment of copd: a review of long-acting muscarinic agonists and long-acting beta-agonists. Interamerican Journal of Health Sciences, 2024(4), 1- 7. https://doi.org/10.59471/ijhsc202497

Montes de Oca M., López-Varela M.V., Acuña A., Schiavi E., Casas A., Tokumoto A., Torres-Duque C.A., Ramírez-Vanegas A., García G., Camelier A., Bergna M., Cohen M., Sanchez-Angarita E., Guzmán S., Czishke K., Barros M & Rey A. (2020). Incorporando nuevas evidencias sobre medicamentos inhalados en la EPOC. Archivos de Bronconeumología. 56(2), 106 - 113. https://doi.org/10.1016/j.arbres.2019.09.023

Rojas-Reyes M. X., García-Morales O. M., Dennis R. J., Karner C. (2016). Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 2016(6), 1 – 51. https://doi.org/10.1002/14651858.CD008532.pub3

Rogliani P., Calzetta L., Braido F., Cazzola M., Clini E., Pelaia G., Rossi A., Scichilone N., Di Marco F. (2018). LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.International Journal of Chronic Obstructive Pulmonary Disease. 2018(13), 3115-3130. https://doi.org/10.2147/COPD.S170606

Montufar-Andrade F., Díaz-Santos G.A., Matiz C., Ali- Munive A., Pacheco M. (2021). Exacerbación aguda de EPOC en la época de COVID-19. Revista Colombiana de Neumología, 32(1), 47-5. https://doi.org/10.30789/rcneumologia.v32.n1.2020.510

Riesco-Miranda J. A., Alcázar B., Inmaculada Alfageme., Casanova C., Celli B., Torres J. P., Jiménez Ruiz C. A. (2017). Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada. Archivos de bronconeumología, 53(10), 574 - 582. https://doi.org/10.1016/j.arbres.2017.03.022

license

How to Cite

Cáceres Cortes, A. P., Báez Ardila , G. F., Molina Ochoa , S. A., & Hernández Zapata , S. A. (2024). Drugs in the Treatment of COPD: A Review of Colombian Drug Therapy. Biociencias, 8(1), 83-97. https://doi.org/10.22490/26194759.9159

Download Citation

Almétricas

Metrics

Metrics Loading ...